INTRODUCTION
cirrhosis, fibrosis, cardiac, renal, and liver diseases, Cirrhosis, deaths
HEPATIC IMPAIRMENT, CIRRHOSIS, FIBROSIS, PATHOPHYSIOLOGY, CIRRHOSIS, CHRONIC INFLAMMATION
Cirrhosis is a devastating outcome of chronic inflammation in the liver, with over 122 million cases of cirrhosis resulting in 1.32 million deaths worldwide.Disrupted nitric oxide (NO) synthesis is a hallmark of PH pathophysiology.Recently developed sGC modulators exhibit diverse effects across cardiac, renal, and liver diseases, including reduction of fibrosis and portal pressure,BI 685509 is an NO-independent sGC activator currently being investigated in patients with PH to slow cirrhosis progression and reduce portal pressure. This Phase Ib clinical trial examined the safety, tolerability, and pharmacokinetics (PK) of BI 685509 in patients with mild (Child–Pugh [CP]-A) or moderate (CP-B) hepatic impairment, using different dosing schemes and compared single doses of BI 685509 in patients and individually matched healthy volunteers (HVs).